Whilst many antidiabetic therapies aggravate weight gain, glucagon-like peptide-1 receptor (GLP-1R) agonists have been shown to promote weight loss in addition to improving glycaemic control . We assessed the clinical effectiveness of the GLP-1R agonist liraglutide in obese people with type 2 diabetes (T2D) , in the clinical practice setting of a National Health Service medical weight management centre in a university teaching hospital in North West England.
